Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
T1D-Plus trial is a randomised, adaptive, open label, parallel group, multi-centre Platform trial in adults with newly diagnosed type 1 diabetes). The T1D Plus trial, funded by JDRF, sponsored by CU, started on 30th September 2022, led by Colin Dayan. Since that time, additional arms of the trial have been funded by separate grants from the Helmsley Charitable Trust and JDRF Australia. Funding was agreed in Dec 2023.
An endpoint in the trial is the recording of glucose levels by a continuous glucose monitoring device. These devices are marketed by different companies with different specifications.
Framework contract: £76,000 total value shared among 2 suppliers. Estimated equal shares shown below.
| Supplier | Identifier | Est. Share | Lots Won | Cross-References |
|---|---|---|---|---|
| 91,200 | - | ~£38,000 | 1 lot Lot 1 | - |
| Dexcom International Limited | FC035846 | ~£38,000 | 1 lot Lot 1 | - |
Taken from this notice, not from Companies House. Check the original notice — details change and are not updated here.
This procurement was divided into 1 lots, each awarded separately.
| Lot | Value | Awarded To | Status |
|---|---|---|---|
| Lot 1 | £76,000 initial term | 91,200 Dexcom International Limited | active |